



6th WORLD CONFERENCE ON
RESEARCH INTEGRITY

HONG KONG
2 - 5 JUNE 2019



Concealed homeopathy: a natural test of peer-review quality

A.Y. Panchin E.V. Dueva V.V. Vlassov

Chronic inflammatory joint diseases

Alcoholism

Attention deficit hyperactivity disorder

Influenza

Other viral and bacterial infections

Meningococcal meningitis

Tick-borne encephalitis

Benign prostatic hypertrophy

Sleep disorders

Erectile dysfunction

HIV

Allergies

Diabetes

Hemorrhagic fever with renal syndrome

Chronic cerebral ischemia


Obesity

Herpes



JOURNAL OF
MEDICAL VIROLOGY

Antiviral Research



sensors



Dose-Response

nature > nutrition & diabetes

Nutrition
& Diabetes

THE JOURNAL OF
SEXUAL MEDICINE
An Official Journal of The International Society for Sexual Medicine



International Journal
of Infectious Diseases
Inflammation

International
Immunopharmacology

Neuropsychiatric Disease and Treatment



Pharmacology Biochemistry and
Behavior

ALTERNATIVE THERAPIES
IN HEALTH AND MEDICINE

Diabetes Research and Clinical
Practice



symmetry

Evidence-Based Complementary and Alternative Medicine

International Journal of Endocrinology

Journal of Diabetes Research

nature > international journal of impotence research

IJIR
Your Sexual Medicine Journal

PLOS | ONE

Antiviral Therapy

**FRONTIERS
IN BIOSCIENCE**

Springer Link

Bulletin of Experimental Biology and
Medicine

JPP JOURNAL OF
Pharmacy and Pharmacology

Release-active (RA) drugs

- Made in Russia
- Based on antibodies
- Taken orally
- After antibodies were diluted... a lot

Release-active drugs



“contains 0.003g of affinity purified antibodies to human interferon gamma”

Fine print: “added to lactose monohydrate in the form of a water– alcohol solution with the concentration of the active form of the active substance not higher than 10^{-16} ng/g”

Release-active drugs



**ЭКСТРЕННАЯ
ПРОФИЛАКТИКА**
клещевого вирусного
энцефалита

Информация для специалистов

анаферон
детский
АНАФЕРОН

Анаферон детский –
для детей с 1 месяца жизни
Анаферон –
для взрослых с 18 лет

Release-active (RA) drugs



A mix of antibodies to the β -subunit of the insulin receptor (IR) and antibodies to endothelial nitric oxide synthase diluted $1:10^{24}$, $1:10^{60}$ and $1:10^{400}$

(19) **United States**

(12) **Patent Application Publication**
Epshtein

(10) **Pub. No.: US 2010/0221258 A1**

(43) **Pub. Date: Sep. 2, 2010**

(54) **METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT**

(75) Inventor: **Oleg Ilich Epshtein, Moscow (RU)**

Correspondence Address:
Kaplan Gilman & Pergament LLP
1480 Route 9 North
Woodbridge, NJ 07095 (US)

(73) Assignee: **Oleg Ilich Epshtein, Moscow (RU)**

(21) Appl. No.: **12/701,128**

(22) Filed: **Feb. 5, 2010**

Related U.S. Application Data

(62) Division of application No. 11/656,225, filed on Jan. 22, 2007, now abandoned, which is a division of application No. 10/311,666, filed on Dec. 17, 2002, now abandoned, filed as application No. PCT/RU01/00239 on Jun. 19, 2001.

(30) **Foreign Application Priority Data**

Jun. 20, 2000 (RU) 2000115594

Publication Classification

(51) **Int. Cl.**
A61K 39/395 (2006.01)
A61P 3/10 (2006.01)
A61P 9/10 (2006.01)
A61P 25/34 (2006.01)
A61P 25/32 (2006.01)
A61P 25/28 (2006.01)
A61P 25/36 (2006.01)

(52) **U.S. Cl.** **424/158.1; 424/172.1**

(57) **ABSTRACT**

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome.

Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on **homeopathic** technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

Examples of research flaws

Table 1 Specific problems identified in discussed papers about release-activity

Journal/Reference	Additional notes on COI statements	Other specific problems identified
<i>Journal of Medical Virology</i> ⁴	The designated section states: ' <i>The authors declare that they have no conflict of interests</i> '. Epstein's affiliation to MMH is not disclosed	Lacks proper randomisation and blinding. Paper contains questionable statements that are not backed by statistical analysis and multiple potential sources of bias ⁴⁶
<i>Journal of Diabetes Research</i> ¹	There is no mention that Epstein is CEO and founder of MMH	Incorrect statistical analysis. We have redone this analysis and shown that contrary to the authors' conclusions, the null hypothesis is actually supported by the data (online supplementary letter 1)
<i>Nutrition & Diabetes</i> ²	There is no mention that Epstein is CEO and founder of MMH	The authors failed to provide images of acquired blots, making it impossible to check the validity of their analysis (online supplementary letter 2)
<i>International Journal of Endocrinology</i> ³	The designated section states: ' <i>The authors declare that they have no conflict of interests</i> '	Lacks blinding and has multiple potential sources of bias (online supplementary letter 3)
<i>PLoS One</i> ⁵	The designated section contains a false statement: ' <i>There are no patents, products in development or marketed products to declare</i> '	Does not account for positioning effects on ELISA blots and fails to use spatial randomisation or at least to benefit from the intermitting of sample and control plates (online supplementary letter 4)
<i>Drug Discovery Today</i> ¹⁶	COI section was omitted. Epstein's affiliation to MMH is not disclosed	Review cites flawed articles (online supplementary letter 5)

COI, conflict of interest; MMH, Materia Medica Holding.

Bulletin of Experimental Biology and Medicine

Volume 135, Issue 7 Supplement, 2003

ISSN: 0007-4888 (Print) 1573-8221 (Online)

In this issue (62 articles)

Page 1 of 4

OriginalPaper

[Regulatory Activity of Ultralow Doses](#)

O. I. Epstein

Pages 8-13

OriginalPaper

[Effects of Phenazepam in Ultralow Doses on Bioelectric Activity of the Brain and Behavior of Rats in Various Models of Anxiety](#)

T. A. Voronina, G. M. Molodavkin...

Pages 14-16

OriginalPaper

[Reaction of Neurons to Alkaloid Agonists of Opioid Receptors during Modulation of Phosphodiesterases](#)

O. I. Epstein, M. B. Shtark, T. A. Zapara...

Pages 17-19

48 papers by O.I. Epstein, who is editor of Issue
90 papers by O.I. Epstein in total

Examples of strange claims by release-active drugs inventor

«The genetic code of any organism is not merely the primary sequence of nucleotides, but also their unique integral (holographic) spatial structure with an intrinsic set of fine supramolecular oscillatory parameters».

«Being transferred over generations, DNA retains the common species-specific spatial parameters within its oscillatory structure and thereby ensures 'attachment' of the future organisms to the common species-specific matrix formed by evolution at the supramolecular level».

Epstein OI. The phenomenon of release activity and the hypothesis of "spatial" homeostasis [In Russian]. Usp Fiziol Nauk 2013;44:54–76

gressing disciplinary boundaries . . . [is] a subversive undertaking since it is likely to violate the sanctuaries of accepted ways of perceiving. Among the most fortified boundaries have been those between the natural sciences and the humanities.

Valerie Greenberg, *Transgressive Readings*

the struggle for the transformation of technology into critical science . . . proceeds on the foundation of the rejection of all presuppositions of scientific methodology and the adoption of a new principle of science.

Stanley Aronson

are many natural scientists, especially physicists, who continue to cling to the notion that science is concerned with social and cultural phenomena. It can have no other concern except perhaps peripherally, the idea that the very nature of the world is in the light of the long post-World War II period, which has seen a world in which the

researcher is concerned with the idea that the very nature of the world is in the light of the long post-World War II period, which has seen a world in which the

criticisms of the long post-World War II period, which has seen a world in which the

supplies of the world in which the

and

Journal hoaxed by gibberish

Academic gloats over mumbo jumbo

By Mitchell Landsberg
Associated Press

SOCIAL



Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice

Sergey A. Tarasov^b, Vladimir V. Zarubaev^{a,*}, Evgeniy A. Gorbunov^b, Svetlana K. Sergiyeva^b, Oleg I. Epstein^b^a Influenza Research Institute, 15/17 Prof. Popova Str., St. Petersburg 197376, Russia^b OOO "NPF "MATERIA MEDICA HOLDING", 3rd Samoyochnyi per. 9, Moscow 127473, Russia

ARTICLE INFO

Article history:

Received 31 March 2011

Revised 2 November 2011

Accepted 29 November 2011

Available online 8 December 2011

Keywords:

Influenza
Pandemic
Antibodies to interferon
Antiviral activity

ABSTRACT

Background: The influenza A virus is a highly infectious agent that causes acute pulmonary diseases. In serious cases, it causes pneumonia which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and elderly people. The present study of purified antibodies to gamma-interferon (Ergoferon) for infection caused by pandemic influenza virus A(H1N1) 2009.

Methods: Balb/c mice were infected with mouse-adapted (H1N1)v. Mortality, weight loss, influenza virus titer of the virus stored in the group of mice treated with oseltamivir and placebo-tri.

Results: The protective activity of AC[®] was demonstrated as a reduction of infectious virus titers in the lung tissue, a decrease of the mortality of treated animals compared to the control group. The protective activity of AC[®] was demonstrated in mice infected with influenza virus A(H1N1)v. Combination of AC[®] with oseltamivir resulted in a decrease of mortality. In conclusion, the results obtained, AC[®] should influence prophylaxis and therapy, in particular in severe



RETRACTION

Retraction: Novel Approach to Activity Evaluation for Release-Active Forms of Anti-Interferon-Gamma Antibodies Based on Enzyme-Linked Immunoassay

The PLOS ONE Editors

dine and rimantadine) and are not effective against influenza B virus (Hayden, 1996). Moreover, rapid emergence of drug-resistance among influenza viruses since mid-90s has greatly compromised the effectiveness of these compounds (CDC, 2008). All pandemic H1N1 viruses tested so far also showed to be drug-resistant (Dawood et al., 2009).

Inhibitors of neuraminidase (oseltamivir, zanamivir and peramivir) have a wider spectrum of activity which includes influenza A and B viruses (Hayden, 2009). Nevertheless, since 2007 rapid emergence and transmission of drug-resistant viruses have been observed (CDC, 2008; Hauge et al., 2009; Dharan et al., 2009). Several strains resistant to inhibitors of neuraminidase were also isolated from pandemic H1N1 virus (Chan et al., 2010). There is therefore a need for both searching for new effective antivirals and development of optimal regimens and combinations of antiviral compounds used in clinics.

Anaferon for children (AC[®]) is an antiviral drug with a wide range of activity (Kudin et al., 2009; Shishkina et al., 2008; Vasil'ev et al., 2008; Epstein, 2005; Sergeev et al., 2004; Martuyshov-Poklad et al., 2004) containing ultra-low doses of antibodies to interferon-gamma, it has been successfully used in medical practice for

1. Introduction

The influenza A virus is a highly infectious agent that causes acute pulmonary diseases. In serious cases, influenza A causes pneumonia which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and elderly people. Outbreaks of highly pathogenic influenza virus infections and appearance of pandemic influenza A virus have triggered the special interest in influenza infection. As of May 2010, more than 214 countries and overseas territories or communities worldwide have reported on laboratory confirmed cases of pandemic influenza A(H1N1) 2009, including more than 18,097 deaths (WHO, 2010). Antiviral drugs occupy an important niche in the management of the disease (Moscona, 2005, 2008). They target virus-specific components and are effective for treatment when administered at the early stage of infection or soon after virus exposure (Moscona, 2008).

Two main classes of anti-influenza drugs are currently accepted for chemotherapy of influenza. Adamantane derivatives (amanta-

* Corresponding author. Tel.: +7 (812) 234 6725; fax: +7 (812) 234 5973. E-mail address: zarubaev@influenza.spb.ru (V.V. Zarubaev).



Efficacy of novel antibody-based drugs against rhinovirus infection: *In vitro* and *in vivo* results

Nataliia V. Petrova^{a,*}, Alexandra G. Emelyanova^a, Evgeniy A. Gorbunov^b, Michael R. Edwards^c, Ross P. Walton^c, Nathan W. Bartlett^c, Julia Anisimko^c, Leila Gogsadze^c, Eteri Bakhsoliani^c, Musa R. Khaitov^d, Sebastian L. Johnston^e, Sergey A. Tarasov^b, Oleg I. Epstein^a^a Research Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia^b OOO "NPF "MATERIA MEDICA HOLDING", 129272 Moscow, Russia^c National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom^d National Research Center "Institute of Immunology" FMBA Russia, 115478 Moscow, Russia

ABSTRACT

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have evaluated the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmacological ingredients) in *in vitro* and *in vivo* experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-inducible gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In mouse model of RV-induced exacerbation of allergic airway inflammation we administered AC and Ergoferon and analyzed its effect on type I (IFN- β), type II (IFN- γ) and type III (IFN- λ) IFNs induction, cell chemokines in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10; CXCL12/KC) levels. It was shown that AC increased OAS1-A production and significantly increased viral replication *in vitro*. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon *in vivo*. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess efficacy against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma.

© 2017 Elsevier B.V. All rights reserved.

1. Introduction

Asthma is the most prevalent respiratory disease affecting 5–10% of adults and 10–15% of children in European societies (Asher et al., 2006). In the worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in

* Corresponding author.

E-mail addresses: nataliia.petrova89@gmail.com (N.V. Petrova), agemelianova@gmail.com (A.G. Emelyanova), gorbunov@materiamedica.ru (E.A. Gorbunov), michael.edwards@imperial.ac.uk (M.R. Edwards), ross.walton@imperial.ac.uk (R.P. Walton), n.bartlett@imperial.ac.uk (N.W. Bartlett), janisencok@imperial.ac.uk (J. Anisimko), lgogsadze@imperial.ac.uk (L. Gogsadze), e.bakhsoliani@imperial.ac.uk (E. Bakhsoliani), mr.khaitov@ncrl.ru (M.R. Khaitov), sjohnston@imperial.ac.uk (S.L. Johnston), tarasova@materiamedica.ru (S.A. Tarasov), Epstein@mail.ru (O.I. Epstein).

childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys). Asthma occurrence has increased over recent decades and this trend is likely continued.

The major morbidity and health care costs related to asthma are a result of acute exacerbations (Weiss and Sullivan, 2001) which are generally triggered by viral infections of the lower respiratory tract (respiratory syncytial viruses (RSV), human metapneumoviruses (hMPV), coronaviruses, influenza viruses and the most common human rhinovirus (RV) (Papadopoulos et al., 2007) (Wood et al., 2011). RV accounts for around 60% of virus induced asthma exacerbations and currently no vaccine or antiviral therapies against them exist. RV-induced asthma exacerbations are therefore a clear unmet medical need.

Inhaled steroids are the mainstay of asthma treatment (Johnston et al., 2005), however, in adults they reduce exacerbation frequency

Notice of concern (to be published)



International Journal of Endocrinology
Volume 2013, Article ID 925874, 4 pages
<http://dx.doi.org/10.1155/2013/925874>

Research Article

Subetta Treatment Increases Adiponectin Secretion by Mature Human Adipocytes *In Vitro*

Jim Nicoll,¹ Evgeniy A. Gorbunov,² Sergey A. Tarasov,² and Oleg I. Epstein²

Journal of Diabetes Research
Volume 2013, Article ID 763125, 9 pages
<http://dx.doi.org/10.1155/2013/763125>

Research Article

The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone

Danielle Bailbé,¹ Erwann Philippe,¹ Evgeniy Gorbunov,² Sergey Tarasov,² Oleg Epstein,² and Bernard Portha¹

JOURNAL OF

MEDICAL VIROLOGY

[Explore this journal >](#)

LETTER TO THE EDITOR

Homeopathy in disguise. Comment on Don et al.: Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model



[Evgenia V. Dueva](#) , [Alexander Y. Panchin](#)



Review

Post screen

Structure and dynamics of the insulin receptor: implications for receptor activation and drug discovery

Libin Ye¹, Suvrajit Maji¹, Narinder Sanghera², Piraveen Gopalasingam², Evgeniy Gorbunov³, Sergey Tarasov³, Oleg Epstein⁴, Judith Klein-Seetharaman^{1,2}  

Review

Post screen

Structure and dynamics of the insulin receptor: implications for receptor activation and drug discovery

Libin Ye¹, Suvrajit Maji¹, Narinder Sanghera², Piraveen Gopalasingam², Evgeniy Gorbunov³, Sergey Tarasov³, Oleg Epstein⁴, Judith Klein-Seetharaman^{1,2} ✉



EBM analysis
General medicine

Drug discovery today: no molecules required

Alexander Y Panchin¹, Nikita N Khromov-Borisov², Evgenia V Dueva³

Author affiliations +

<http://dx.doi.org/10.1136/bmiebm-2018-111121>

Recent development in Russia

- 2017 «release-activity» is labeled «pseudoscience» along with homeopathy by Commission on Pseudoscience of Russian academy of Sciences
- 2017 Ministry of Health promises commission to evaluate homeopathy
- Commission is never created
- 2018 Ministry of Science names manufacturers of RA drugs «the most damaging pseudoscientific project»
- 2018 Newspaper «Troitskiy Variant Nauka» publishes criticism of «release active drugs»
- 2018 Materia Medica sues «Troitskiy Variant Nauka» and three scientists
- 2019 Court ends with «Peace treaty»

Reasons for my trip to Hong Kong

- We want to inform the community of the issue
- We need help and advice
- The case of RA drugs might reveal how other false-positive results get published in biomedical journals

Why Psychologists Must Change the Way They Analyze Their Data: The Case of Psi: Comment on Bem (2011)

Eric-Jan Wagenmakers, Ruud Wetzels, Denny Borsboom, and Han L. J. van der Maas
University of Amsterdam

Acknowledgments

Co-authors on BMJ EBM paper:

Evgenia Dueva

Nikita Khromov-Borisov

Interaction with other journals after BMJ EBM paper:

Vasiliy Vlassov

For stepping in for research integrity:

Editors of PLoS ONE,
Antiviral Research,
BMJ EBM,
Medical Virology,
Matt Hodgkinson, Head of
Research Integrity (Hindawi)
(hope this list will be
continued)

For informing the community:

Steven Novella
Steven Salzberg
Derek Lowe
James Coyne
Michael Gelfand

Retraction Watch
Alison McCook
Adam Marcus

and others

Contact: alexpanchin@yahoo.com